Search filters
Filters
Clear All

Phase

  • 1
  • 1
  • 1
  • 4
  • 3
  • 2
  • 148
  • 15
  • 24
  • 160
  • 187
  • 64

Found 199 Neoplasms trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Testing the addition of a new immunotherapy drug, Atezolizumab (MPDL3280A), to the usual chemoradiation (CRT) therapy treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

18 - 100
All genders
Phase 2/3
Interventional
This study is being done to answer the following question: Can we lower the chance of small cell lung cancer growing or spreading by adding an immunotherapy drug (atezolizumab) to the usual treatment for this type of cancer?
Learn More

Immunological Profile Changes In Patients with Advanced Non-Small Cell Lung Cancer Undergoing Treatment with Checkpoint Inhibitor Monotherapy

18 - 100
Accepts healthy volunteer
All genders
Researchers would like to study how certain biomarkers (signs in your genes that show how well your body responds to a treatment for a disease or condition) change before, during, and after your standard of care treatment for your non-small cell lung cancer (NSCLC). The purpose of this study is …
Learn More

PHO-COG-FALLON-ANBL00B1; Neuroblastoma Biology Studies

30 or below
All genders
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma.
Learn More

A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

18 - 100
All genders
Phase 2/3
Interventional
This study will compare the effects, good and/or bad, of radiation and chemotherapy to radiation alone in salivary gland cancer to find out which is better at reducing the chance that the cancer will come back.
Learn More

Total Cancer Care: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer

2 - 100
All genders
The purpose of this research study is to collect and store biospecimens and personal health information to use in future research studies. This research study is to build a large database (of information and specimens) to find better ways to prevent, diagnose and treat cancer.
Learn More

One-on-one exercise program in adolescent and young adult cancer survivors with a certified clinical cancer exercise specialist

15 - 39
All genders
The purpose of this study is to better understand whether or not adolescent and young adult cancer survivors can complete an exercise program after treatment and whether or not that program may impact cardiovascular strength and balance. Researchers will also study changes in the blood and body that may occur …
Learn More

Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)

18 - 100
All genders
The purpose of this study is to test the safety and efficacy of combining two drugs, ixazomib and romidepsin. It will also measure the percentage of patients whose tumor completely resolves after receiving ixazomib and romidepsin.
Learn More

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

3 - 21
All genders
This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma.
Learn More

Telephone Support for Metastatic Breast Cancer Patients

18 - 100
Female
The purpose of this study is to see if telephone support programs help patients adjust to metastatic breast cancer.
Learn More

Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib Big Ten Cancer Research Consortium BTCRC-HEM17-092

18 - 100
All genders
Phase 1/2
The purpose of this study is to test the safety and efficacy of combining two drugs, ixazomib and TAK-659. It will also evaluate the number of patients whose tumor responded after receiving ixazomib and TAK-659.
Learn More
91 - 100 of 199